Article By:
The Fly
Friday, December 30, 2016 11:41 AM EDT
Innocoll Holdings announced that it has received a Refusal to File letter from the U.S. Food and Drug Administration for Xaracoll, the company's product candidate for the treatment of postsurgical pain.
In this article: INNL Also: PCRX
